Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02819843 · ClinicalTrials.gov registry record · Phase 2
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02819843: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02819843 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02819843, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.
Interventions
- RADIATION Hypofractionated Radiotherapy
- DRUG TALIMOGENE LAHERPAREPVEC (TVEC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-06-21 |
| Est. Completion | 2024-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02819843
The ClinicalTrials.gov registry entry for NCT02819843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hypofractionated Radiotherapy is the first listed.
NCT02819843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02819843 about?
NCT02819843 is a clinical study titled "A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors". The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.
What is the current status of trial NCT02819843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-06-21. Estimated completion is 2024-02-22.
What interventions are being tested in trial NCT02819843?
The interventions under investigation include: Hypofractionated Radiotherapy (RADIATION), TALIMOGENE LAHERPAREPVEC (TVEC) (DRUG).
Who is sponsoring clinical trial NCT02819843?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.